155 related articles for article (PubMed ID: 31566378)
1. Modeling MEK4 Kinase Inhibitors through Perturbed Electrostatic Potential Charges.
Mishra RK; Deibler KK; Clutter MR; Vagadia PP; O'Connor M; Schiltz GE; Bergan R; Scheidt KA
J Chem Inf Model; 2019 Oct; 59(10):4460-4466. PubMed ID: 31566378
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors.
Deibler KK; Schiltz GE; Clutter MR; Mishra RK; Vagadia PP; O'Connor M; George MD; Gordon R; Fowler G; Bergan R; Scheidt KA
ChemMedChem; 2019 Mar; 14(6):615-620. PubMed ID: 30707493
[TBL] [Abstract][Full Text] [Related]
3. A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.
Deibler KK; Mishra RK; Clutter MR; Antanasijevic A; Bergan R; Caffrey M; Scheidt KA
ACS Chem Biol; 2017 May; 12(5):1245-1256. PubMed ID: 28263556
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
Ravindra GK; Achaiah G; Sastry GN
Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
[TBL] [Abstract][Full Text] [Related]
5. Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome.
Martin E; Mukherjee P
J Chem Inf Model; 2012 Jan; 52(1):156-70. PubMed ID: 22133092
[TBL] [Abstract][Full Text] [Related]
6. Multi-objective Optimization of Benzamide Derivatives as Rho Kinase Inhibitors.
Cardoso Gajo G; Rodrigues Silva D; Barigye SJ; da Cunha EFF
Mol Inform; 2018 Mar; 37(3):. PubMed ID: 28876533
[TBL] [Abstract][Full Text] [Related]
7. p38 Mitogen-activated protein kinase inhibitors: a review on pharmacophore mapping and QSAR studies.
Gangwal RP; Bhadauriya A; Damre MV; Dhoke GV; Sangamwar AT
Curr Top Med Chem; 2013; 13(9):1015-35. PubMed ID: 23651481
[TBL] [Abstract][Full Text] [Related]
8. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
Zhang G; Ren Y
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
[TBL] [Abstract][Full Text] [Related]
9. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
Bavi R; Kumar R; Choi L; Woo Lee K
PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
[TBL] [Abstract][Full Text] [Related]
10. Modeling of p38 mitogen-activated protein kinase inhibitors using the Catalyst HypoGen and k-nearest neighbor QSAR methods.
Xiao Z; Varma S; Xiao YD; Tropsha A
J Mol Graph Model; 2004 Oct; 23(2):129-38. PubMed ID: 15363455
[TBL] [Abstract][Full Text] [Related]
11. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
12. Predictive QSAR modeling workflow, model applicability domains, and virtual screening.
Tropsha A; Golbraikh A
Curr Pharm Des; 2007; 13(34):3494-504. PubMed ID: 18220786
[TBL] [Abstract][Full Text] [Related]
13. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
Holder S; Lilly M; Brown ML
Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
[TBL] [Abstract][Full Text] [Related]
14. Kinase inhibitor recognition by use of a multivariable QSAR model.
Sprous DG; Zhang J; Zhang L; Wang Z; Tepper MA
J Mol Graph Model; 2006 Jan; 24(4):278-95. PubMed ID: 16253531
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors.
Chaube U; Bhatt H
Mol Divers; 2017 Aug; 21(3):741-759. PubMed ID: 28577112
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling-driven approach for identification of Janus kinase 1 inhibitors through 3D-QSAR, docking and molecular dynamics simulations.
Itteboina R; Ballu S; Sivan SK; Manga V
J Recept Signal Transduct Res; 2017 Oct; 37(5):453-469. PubMed ID: 28537140
[TBL] [Abstract][Full Text] [Related]
17. Characterizing the Chemical Space of ERK2 Kinase Inhibitors Using Descriptors Computed from Molecular Dynamics Trajectories.
Ash J; Fourches D
J Chem Inf Model; 2017 Jun; 57(6):1286-1299. PubMed ID: 28471171
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
[TBL] [Abstract][Full Text] [Related]
19. Computational insights into the interaction of small molecule inhibitors with HRI kinase domain.
Palrecha S; Lakade D; Kulkarni A; Pal JK; Joshi M
J Biomol Struct Dyn; 2019 Apr; 37(7):1715-1723. PubMed ID: 29663856
[TBL] [Abstract][Full Text] [Related]
20. Free-energy force-field three-dimensional quantitative structure-activity relationship analysis of a set of p38-mitogen activated protein kinase inhibitors.
Romeiro NC; Albuquerque MG; de Alencastro RB; Ravi M; Hopfinger AJ
J Mol Model; 2006 Sep; 12(6):855-68. PubMed ID: 16541250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
